FindTrial
Sign In

Tumor removal

PROCEDURE3 trials

Sponsors

DNAtrix, Inc., University Hospital, Clermont-Ferrand, Norwegian Department of Health and Social Affairs

Conditions

Brain CancerCachexiaCentral Nervous System DiseasesColorectal CancerHead and Neck CancerSquamous Cell CarcinomaTreatment Side Effects

Phase 1

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
CompletedNCT00805376
DNAtrix, Inc.Brain Cancer, Central Nervous System Diseases
Start: 2009-02-28End: 2015-02-28Updated: 2018-07-16

Unknown Phase

Role of Myostatin, Activin A and Follistatin Cachexia of ENT Cancers
CompletedNCT03162042
University Hospital, Clermont-FerrandCachexia, Head and Neck Cancer, Squamous Cell Carcinoma
Start: 2015-11-02End: 2017-05-31Updated: 2017-05-22
Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR
RecruitingNCT06057350
Norwegian Department of Health and Social AffairsColorectal Cancer, Treatment Side Effects
Start: 2023-10-27End: 2033-09-30Target: 304Updated: 2024-02-16

Related Papers

Abstract 2895: JAK inhibition enhances virotherapy in gliomas by modulating interferon-driven resistance
Cancer Research2026-04-03
TMIC-53. Novel therapy for diffuse midline glioma: Targeting oncohistone drivers with P300/CBP inhibition and Delta-24-RGD
Neuro-Oncology2025-11-01
IMMU-39. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD
Neuro-Oncology2025-11-01
IMMU-48. Ruxolitinib enhances viroimmunotherapy of gliomas: targeting JAK-guided immunosuppressive pathways
Neuro-Oncology2025-11-01
IMMU-63. Uncovering alternative innate immunity pathways in glioma viroimmunotherapy
Neuro-Oncology2025-11-01
IMMU-35. TARGETING THE AHR IMMUNOMETABOLIC HUB DURING VIROIMMUNOTHERAPY OF GLIOMAS
Neuro-Oncology2024-11-01
IMMU-11. GUARDIANS OF INNATE IMMUNE ACTIVATION: CRUCIAL ROLES OF NONO AND CGAMP IN GLIOMA VIROTHERAPY
Neuro-Oncology2024-11-01
IMMU-56. TARGETING NONO IN GLIOMA VIROIMMUNOTHERAPY
Neuro-Oncology2023-11-011 citations
1097 New immunomodulatory roles of NONO pathway during glioma virotherapy
Regular and Young Investigator Award Abstracts2023-10-31
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
Abstract 3263: Implications for cancer viroimmunotherapy: a new adenovirus capsid sensor
Cancer Research2023-04-04
IMMU-11. NONO IS A NEW ADENOVIRUS SENSOR: IMPLICATION FOR VIROTHERAPY
Neuro-Oncology2022-11-01
EXTH-27. ACTIVATING THE IMMUNITY WITHIN THE TUMOR USING VIROIMMUNOTHERAPY: DELTA-24-RGD ONCOLYTIC ADENOVIRUS ARMED WITH THE IMMUNOPOSITIVE REGULATOR GITRL
Neuro-Oncology2019-11-011 citations
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
2019-05-28111 citations
ATRT-03. EFFICACY OF THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD AS A THERAPEUTIC AGENT FOR THE TREATMENT OF PEDIATRIC EMBRYONAL BRAIN TUMORS
Neuro-Oncology2019-04-01
Abstract LB-235: Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas
Cancer Research2017-07-01